Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

Stock Research Monitor: ZGNX, DEPO, and DRRX

LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration. Ahead of today’s trading session, WallStEquities.com monitors Zogenix Inc. (NASDAQ: ZGNX), Depomed Inc. (NASDAQ: DEPO), DURECT Corp. (NASDAQ: DRRX), and Endo International PLC (NASDAQ: ENDP). These stocks are part of the Healthcare sector, which is the range of companies and non-profit organizations that provide medical services, manufacture medical equipment, and develop pharmaceuticals. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Zogenix

On Wednesday, shares in Emeryville, California headquartered Zogenix Inc. recorded a trading volume of 1.05 million shares, which was above their three months average volume of 489,030 shares. The stock ended at $42.75, rising slightly by 0.47% from the last trading session. The Company’s shares have gained 11.33% in the last month and 193.81% over the past year. The stock is trading above its 50-day and 200-day moving averages by 7.18% and 20.38%, respectively. Furthermore, shares of Zogenix, which develops and commercializes therapies for the treatment of central nervous system disorders in the US, have a Relative Strength Index (RSI) of 67.80.

On June 01st, 2018, Zogenix has issued inducement awards to four new, non-executive employees. The inducement awards consist of options to purchase an aggregate of 28,200 shares of the Company’s common stock. The options have a ten-year term and an exercise price equal to $42.50, the fair market value of the common stock on the date of grant. Get the full research report on ZGNX for free by clicking below at:

www.wallstequities.com/registration/?symbol=ZGNX

Depomed

Newark, California headquartered Depomed Inc.’s stock finished yesterday’s session 1.10% higher at $6.42 with a total trading volume of 458,288 shares. The Company’s shares have gained 4.73% in the last month. The stock is trading below its 50-day moving average by 3.85%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 45.79.

On June 05th, 2018, Depomed announced that it has appointed Phillip B. Donenberg as CFO and Senior Vice President, effective July 16th, 2018. Mr. Donenberg will succeed August J. Moretti, who has served as CFO since January 2012. Mr. Moretti will remain CFO through the transition until July 16th, 2018, at which time he intends to seek another position in the San Francisco, California area. The free technical report on DEPO can be accessed at:

www.wallstequities.com/registration/?symbol=DEPO

DURECT

At the close of trading on Wednesday, shares in Cupertino, California headquartered DURECT Corp. saw a slight decline of 0.48%, ending the day at $2.06. The stock recorded a trading volume of 665,435 shares. The Company’s shares have advanced 15.08% in the last month, 18.39% in the previous three months, and 70.25% over the past year. The stock is trading 35.10% above its 200-day moving average. Moreover, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 53.58.

On May 09th, 2018, DURECT (DRRX) announced that it has entered into an amendment to the development and commercialization agreement with Sandoz AG, a division of Novartis, regarding POSIMIR® (SABER®-bupivacaine) in the US. Pursuant to the amended agreement, DRRX is now eligible for up to $30 million n milestone payments based on NDA approval, and remains eligible for up to an additional $230 million in sales-based milestones. Sign up for free on Wall St. Equities and claim the latest report on DRRX at:

www.wallstequities.com/registration/?symbol=DRRX

Endo International

Dublin, Ireland headquartered Endo International PLC’s shares ended the day 19.05% higher at $7.75. A total volume of 17.71 million shares was traded, which was above their three months average volume of 4.75 million shares. The stock has gained 37.90% in the last month and 7.19% over the previous three months. The Company’s shares are trading 32.03% above their 50-day moving average and 8.52% above their 200-day moving average. Additionally, shares of Endo International, which manufactures and sells generic and branded pharmaceuticals in the US, Canada, and internationally, have an RSI of 81.27. See the free research coverage on ENDP at:

www.wallstequities.com/registration/?symbol=ENDP

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501991